FDA Warns of Nicotine Candy as Public Health Crisis

Aug.19.2022
FDA Warns of Nicotine Candy as Public Health Crisis
The FDA has issued a warning to Krave Nic, a Florida-based candy maker, to remove their nicotine candy from the market.

The FDA has declared it a "public health crisis waiting to happen" and has issued a warning to a Florida manufacturer to pull its nicotine-laced gummies off the market. The incident is notable because few people were aware of the product's existence prior to the FDA's announcement, including news releases, Twitter posts and social media attaboy posts from tobacco control organizations such as Truth Initiative. Gregory Conley, president of the American Vaping Association, tweeted, "The FDA has just cancelled a product used by 23 Americans on a regular basis." "The long, legendary history of tobacco control has been to distract attention with shiny new objects while cigarettes continue to be sold.


Krave Nic, a soft candy manufacturer based in Florida, has been cited by the FDA for selling candy containing synthetic nicotine without submitting a premarket tobacco application (PMTA) or obtaining marketing authorization from the agency. Earlier this year, the FDA received authorization over synthetic nicotine, and since July 14th, selling any products with synthetic nicotine without authorization is technically illegal. The warning letter includes a comprehensive press release from the FDA's Center for Tobacco Products, featuring quotes from FDA Commissioner Robert Califf and CTP Director Brian King, suggesting that nicotine candy may pose a serious public health threat.


We remain firmly committed to using regulatory and law enforcement resources to curb all illegal marketing of tobacco products, especially those that are easily confused with items consumed frequently by young people, such as candy," said Gold. According to the FDA, Krave's nicotine gum (which contains 1 milligram of nicotine per box, with 12 pieces per box) poses a significant risk to children. "Studies have shown that ingestion of 1 to 4 milligrams of nicotine, depending on the child's weight, can cause severe toxicity in children under six," the press release said. "However, nicotine poisoning in young people of any age can lead to nausea, vomiting, stomach pain, increased blood pressure and heart rate, seizures, respiratory failure, coma and even death.


The FDA has approved nicotine gum and lozenges that are produced by pharmaceutical companies and sold over-the-counter. These products contain more nicotine than Krave gum and have appealing flavors. They are sold in large quantities and available in tens of thousands of stores nationwide. "Nicotine gum is a public health crisis waiting to happen among our young people, especially as we enter a new school year," said Califf. "We want parents to understand these products and the potential health consequences for children of all ages, including the toxicity to toddlers and the allure of these addictive products to our young people. When illicit products enter the market, the FDA will not sit idly by.


This statement is a prime example of an institution that goes too far in its efforts to be correct, losing all sense of purpose and proportionality, and now flailing in the shadows. As we have explained, when faced with external pressure, the FDA often attacks insignificant threats with absurd ferocity.


Today's action should serve as a wake-up call to the manufacturers of these illegal products, and the FDA is actively working to investigate any wrongdoing and seek corrective measures," said CTP Director King. The warning letter gives Krave Nic 15 working days to respond, "describing the actions taken to address any violations and bring your products into compliance." According to Krave's website, this should not be difficult as these products have already been discontinued. It is unclear at this time whether these gummies were eliminated due to the FDA's letter or a lack of retail interest.


Statement


This article is compiled from third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in our translating ability, the translated article may not fully express the same meaning as the original text. Therefore, please refer to the original text for accuracy.


In regards to any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions, 2FIRSTS maintains complete alignment with the Chinese government.


The compilation of information is owned by the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.
Regulations
Oct.09
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23